Glemorstart-M V 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, designed for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea, enhances pancreatic insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and increases peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the gastrointestinal tract, reducing postprandial hyperglycemia. The sustained-release formulation ensures a gradual and prolonged drug release, optimizing therapeutic efficacy while minimizing gastrointestinal side effects commonly associated with Metformin and Voglibose. Glemorstart-M V 1 Tablet SR is indicated for patients inadequately controlled by diet and exercise alone or those requiring combination therapy to achieve optimal blood glucose levels. It is essential to monitor renal function and hepatic parameters periodically during therapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or a history of lactic acidosis. This combination therapy offers a multifaceted approach to glycemic control by targeting different pathophysiological mechanisms of type 2 diabetes, thereby improving patient compliance and overall metabolic outcomes when used alongside lifestyle modifications.